Effect of Direct Oral Anticoagulants Versus Traditional Anticoagulation in Budd-Chiari Syndrome.

ABSTRACT: BackgroundThis systematic review aimed to evaluate the comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus traditional anticoagulants, including vitamin K antagonists (VKAs) and low-molecular-weight heparins (LMWHs), in the treatment of Budd-Chiari Syndrome (BCS).MethodsA comprehensive literature search was conducted in the PubMed and Embase databases up to July 2025. Studies were selected based on predefined inclusion criteria, focusing on patients with BCS who received DOACs (specifically dabigatran, rivaroxaban, apixaban, or edoxaban) compared to those treated with VKAs or LMWHs.ResultsOf 68 identified records, two retrospective studies met the inclusion criteria. Sharma et al (India, n = 98) compared dabigatran with VKAs after percutaneous endovascular int

SUBMITTER: Wu X 

PROVIDER: S-EPMC12484904 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature